ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial

E. Favi, N. Silvestrini, J. Pedroso, M. Salerno, G. Spagnoletti, V. Bianchi, J. Romagnoli, F. Citterio

Surgery - Renal Transplantation, Catholic University, Rome, Italy

Meeting: 2013 American Transplant Congress

Abstract number: B950

Related Abstracts
  • 1-Year Outcomes of a Prospective, Open Label, Randomized, Controlled Trial of Standard vs Extended-Release Tacrolimus as Maintenance Monotherapy in Kidney Transplantation after Alemtuzumab Induction with Rapid Steroid Withdrawal (TAESR Trial)
  • Multicenter Randomized Clinical Investigation for the Safety and Efficacy of Advagraf® (Extended-Release Tacrolimus) vs. Prograf® (Twice-Daily Tacrolimus) in De Novo Korean Adult Kidney Recipients

Purpose. Aim of this randomized phase 2 trial in kidney transplantation was to compare an immunosuppressive regimen based on the association of low-dose ER-tacrolimus and everolimus to a standard dose ER-tacrolimus and MMF regimen. Results at 1 year of follow up are presented.

Methods. Fortytwo primary deceased donor kidney transplant recipients were randomly assigned before transplantation to receive ER-tacrolimus plus everolimus (EVE group: 21 patients) or ER-tacrolimus plus mycophenolate mofetil (MMF group: 21 patients). As induction therapy all patients received a combination of basiliximab (20 mg IV on day 0 and day 4), thymoglobulin (50 mg/day IV from day 0 to day 3) and steroids (methylprednisolone 500 mg IV on day 0 and 125 mg IV on day 1). Assigned study medications were orally administered once daily starting on p.o. day 4. Six months after transplantation steroids were selectively withdrawn in patients with no acute rejection episodes, serum creatinine < 2 mg/dL and proteinuria < 300 mg/L/24 h.

Results. Demographics were similar between groups. Efficacy and safety parameters after 1 year of follow up are summarized in table 1.

Efficacy and safety parameters at 1 year of follow up.
  MMF EVE p
Patient survival (%) 100 95 ns
Gaft survival (%) 100 95 ns
BPAR (%) 5 0 ns
DSA + (%) 10 15 ns
MDRD (mL/min/1.73m²) 51±17 52±21 ns
Proteinuria 24h (mg/L) 0.1±0.2 0.2±0.2 ns
Hemoglobin (g/dL) 12.7±1.5 13±1.7 ns
WBC count (cell x 10^9/L) 6.9±2.5 6±1.5 ns
Platelet count (cell x 10^9/L) 290±160 218±72 ns
Total cholesterol (mg/dL) 208±52 212±39 ns
Triglycerides (mg/dL) 160±109 178±112 ns
Dislipidemia on treatment (%) 35 40 ns
Hypertension on treatment (%) 76 85 ns
NODAT (%) 5 11 ns
CMV infection (%) 38 15 ns
CMV disease (%) 0 0 ns
PVAN (%) 0 0 ns
UTI (%) 43 40 ns
PTLD (%) 0 0 ns
Wound dehiscence (%) 0 0 ns
ER-tacrolimus C0 (ng/mL) 6.7±1.5 3.9±1.8 <0.01
Steroid withdrawal (%) 43 45 ns
Drop out (%)
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Favi E, Silvestrini N, Pedroso J, Salerno M, Spagnoletti G, Bianchi V, Romagnoli J, Citterio F. Extended-Release Tacrolimus Plus Everolimus vs Extended-Release Tacrolimus Plus Micophenolate Mofetil in Primary Deceased Donor Kidney Transplant Recipients: 1-Year Results of an Open Label, Randomized Phase 2 Clinical Trial [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/extended-release-tacrolimus-plus-everolimus-vs-extended-release-tacrolimus-plus-micophenolate-mofetil-in-primary-deceased-donor-kidney-transplant-recipients-1-year-results-of-an-open-label-randomize/. Accessed February 28, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.